Longevity & AgingAI and Gene Editing Team Up to Rewire Immune Cells Against Cancer
Cancer immunotherapy is entering a new era. Aaron Edwards, CEO of KiraGen Bio, explains how his company combines advanced gene editing with AI-powered drug discovery to create off-the-shelf CAR-T cell therapies. Unlike traditional CAR-T treatments that work well in blood cancers, solid tumors like glioblastoma have long resisted these approaches. KiraGen is tackling this by editing immune cells at multiple gene sites simultaneously, making them more effective at penetrating and destroying hard-to-treat tumors. The AI platform helps identify the best combinations of genetic modifications to maximize therapeutic impact. For longevity-minded individuals, this represents a meaningful advance in cancer prevention and treatment — one of the leading causes of premature death and lost healthspan globally.
